Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2024

Open Access 01-12-2024 | Spirometry | Research

A comparative study of bronchodilator response: utilizing pre-bronchodilator versus predicted normal values

Authors: Afe Alexis, Naresh M. Punjabi, Kyle Grealis, Adam Wanner

Published in: BMC Pulmonary Medicine | Issue 1/2024

Login to get access

Abstract

Background

A positive bronchodilator response has been defined as a 12% increase in the forced expiratory volume in one second (FEV1) or forced vital capacity (FVC) from their respective pre-bronchodilator values, combined with at least a 0.2 L absolute change. Recent recommendations suggested the use of the percent change in FEV1 and FVC relative to their predicted normal values without having applied them in patients with airflow obstruction. The aim of the current study was to compare the two approaches over a wide range of pre-bronchodilator FEV1 and FVC values.

Methods

A retrospective review of consecutive patients undergoing spirometry and bronchodilator testing was completed. The change in FEV1 and FVC with a bronchodilator was expressed relative to the pre-bronchodilator and predicted normal FEV1 and FVC.

Results

In 1,040 patients with a non-paradoxical change in FEV1, 19.0% had a ≥ 12% change in FEV1 using their pre-bronchodilator value compared to 5.7% using their predicted normal value. For FVC, the respective values were 12.7% vs. 5.8%. The difference was retained in patients with a ≥ 0.2 L change in FEV1 or FVC. In unobstructed patients, the upper threshold (two standard deviations above the mean) of the bronchodilator response was 14% for FEV1 and 10% for FVC using predicted normal values.

Conclusions

Expressing the percent change in FEV1 and FVC relative to predicted normal values reduces the over-estimation of the bronchodilator response, especially in patients with a very low pre-bronchodilator FEV1, including in those with a ≥ 0.2 L change in FEV1. Irrespective of pre-bronchodilator values, a ≥ 14% change in FEV1 and ≥ 10% change in FVC relative to the predicted normal values could be considered a positive bronchodilator response.
Literature
1.
go back to reference Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948–68.CrossRefPubMed Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948–68.CrossRefPubMed
2.
go back to reference Miller RA, Walker RD, Carson J, Coles M, Coyne R, Dalsgaard I, Gieseker C, Hsu HM, Mathers JJ, Papapetropoulou M, et al. Standardization of a broth microdilution susceptibility testing method to determine minimum inhibitory concentrations of aquatic bacteria. Dis Aquat Organ. 2005;64(3):211–22.CrossRefPubMed Miller RA, Walker RD, Carson J, Coles M, Coyne R, Dalsgaard I, Gieseker C, Hsu HM, Mathers JJ, Papapetropoulou M, et al. Standardization of a broth microdilution susceptibility testing method to determine minimum inhibitory concentrations of aquatic bacteria. Dis Aquat Organ. 2005;64(3):211–22.CrossRefPubMed
3.
go back to reference Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CP, et al. Standardisation of the measurement of lung volumes. Eur Respir J. 2005;26(3):511–22.CrossRefPubMed Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CP, et al. Standardisation of the measurement of lung volumes. Eur Respir J. 2005;26(3):511–22.CrossRefPubMed
4.
go back to reference Stanojevic S, Kaminsky DA, Miller MR, Thompson B, Aliverti A, Barjaktarevic I, Cooper BG, Culver B, Derom E, Hall GL et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J 2022, 60(1). Stanojevic S, Kaminsky DA, Miller MR, Thompson B, Aliverti A, Barjaktarevic I, Cooper BG, Culver B, Derom E, Hall GL et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J 2022, 60(1).
5.
go back to reference Tan WC, Vollmer WM, Lamprecht B, Mannino DM, Jithoo A, Nizankowska-Mogilnicka E, Mejza F, Gislason T, Burney PG, Buist AS, et al. Worldwide patterns of bronchodilator responsiveness: results from the Burden of Obstructive Lung Disease study. Thorax. 2012;67(8):718–26.CrossRefPubMed Tan WC, Vollmer WM, Lamprecht B, Mannino DM, Jithoo A, Nizankowska-Mogilnicka E, Mejza F, Gislason T, Burney PG, Buist AS, et al. Worldwide patterns of bronchodilator responsiveness: results from the Burden of Obstructive Lung Disease study. Thorax. 2012;67(8):718–26.CrossRefPubMed
6.
go back to reference Hansen JE, Dilektasli AG, Porszasz J, Stringer WW, Pak Y, Rossiter HB, Casaburi R. A New Bronchodilator Response Grading Strategy identifies distinct patient populations. Ann Am Thorac Soc. 2019;16(12):1504–17.CrossRefPubMedPubMedCentral Hansen JE, Dilektasli AG, Porszasz J, Stringer WW, Pak Y, Rossiter HB, Casaburi R. A New Bronchodilator Response Grading Strategy identifies distinct patient populations. Ann Am Thorac Soc. 2019;16(12):1504–17.CrossRefPubMedPubMedCentral
7.
go back to reference Gross NJ, Co E, Skorodin MS. Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects. Chest. 1989;96(5):984–7.CrossRefPubMed Gross NJ, Co E, Skorodin MS. Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects. Chest. 1989;96(5):984–7.CrossRefPubMed
8.
go back to reference Li Y, Lin J, Wang Z, Wang Z, Tan L, Liu S, Huang J, Gao Y, Zheng J. Bronchodilator Responsiveness defined by the 2005 and 2021 ERS/ATS criteria in patients with Asthma as Well as Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2022;17:2623–33.CrossRefPubMedPubMedCentral Li Y, Lin J, Wang Z, Wang Z, Tan L, Liu S, Huang J, Gao Y, Zheng J. Bronchodilator Responsiveness defined by the 2005 and 2021 ERS/ATS criteria in patients with Asthma as Well as Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2022;17:2623–33.CrossRefPubMedPubMedCentral
9.
go back to reference Chaiwong W, Deesomchok A, Pothirat C, Duangjit P, Liwsrisakun C. Impact of the new European respiratory (ERS)/American thoracic society (ATS) pulmonary function test interpretation guidelines 2021 on the interpretation of bronchodilator responsiveness in subjects with airway obstruction. Respir Med. 2023;220:107460.CrossRefPubMed Chaiwong W, Deesomchok A, Pothirat C, Duangjit P, Liwsrisakun C. Impact of the new European respiratory (ERS)/American thoracic society (ATS) pulmonary function test interpretation guidelines 2021 on the interpretation of bronchodilator responsiveness in subjects with airway obstruction. Respir Med. 2023;220:107460.CrossRefPubMed
10.
go back to reference Beasley R, Hughes R, Agusti A, Calverley P, Chipps B, Del Olmo R, Papi A, Price D, Reddel H, Mullerova H et al. Prevalence, Diagnostic Utility and Associated characteristics of Bronchodilator Responsiveness. Am J Respir Crit Care Med 2023. Beasley R, Hughes R, Agusti A, Calverley P, Chipps B, Del Olmo R, Papi A, Price D, Reddel H, Mullerova H et al. Prevalence, Diagnostic Utility and Associated characteristics of Bronchodilator Responsiveness. Am J Respir Crit Care Med 2023.
11.
go back to reference Beydon N, Rosenfeld M. Comparison of bronchodilator responsiveness in asthmatic children using 2021 or 2005 ATS/ERS guidelines. Pediatr Pulmonol. 2024;59(1):233–5.CrossRefPubMed Beydon N, Rosenfeld M. Comparison of bronchodilator responsiveness in asthmatic children using 2021 or 2005 ATS/ERS guidelines. Pediatr Pulmonol. 2024;59(1):233–5.CrossRefPubMed
Metadata
Title
A comparative study of bronchodilator response: utilizing pre-bronchodilator versus predicted normal values
Authors
Afe Alexis
Naresh M. Punjabi
Kyle Grealis
Adam Wanner
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2024
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-024-02859-4

Other articles of this Issue 1/2024

BMC Pulmonary Medicine 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine